The MarketWatch News Department was not involved in the creation of this content. Guidance validates the comprehensive approach Bracco has advanced for more than three decades NEEDHAM, Mass., April 13 ...
New Clinical Indications Statement Expands Recommendations for Cardiac PET and Myocardial Blood Flow Quantification Based on the clinical and scientific evidence now available, there are no clinical ...
GE HealthCare GEHC recently unveiled new advancements in precision cardiac care at the 2025 SNMMI annual meeting in New Orleans, with a spotlight on Flyrcado—its FDA-approved Positron Emission ...
GE HealthCare’s FDA-approved flurpiridaz F 18 PET radiotracer, Flyrcado, delivers higher diagnostic efficacy in patients with known or suspected coronary artery disease (CAD), compared to SPECT MPI, ...
The significantly longer half-life of Flyrcado (109 minutes) allows for it to be manufactured at an offsite pharmacy and delivered as a ready-to-use unit dose. The approval was supported by data from ...
Patients in East Texas now have access to a new, advanced form of heart-imaging technology that physicians say can provide clearer, more accurate evaluations of blood flow to the heart and help detect ...
Based on the clinical and scientific evidence now available, there are no clinical scenarios or patient subgroups where cardiac PET with myocardial blood flow should be excluded.” — Timothy Bateman, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results